Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2001-06-04
2008-11-11
Yaen, Christopher (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
Reexamination Certificate
active
07449557
ABSTRACT:
The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5112298 (1992-05-01), Prince et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5232833 (1993-08-01), Sanders et al.
patent: 5273965 (1993-12-01), Kensil et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5554293 (1996-09-01), Uhoch
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5637082 (1997-06-01), Pages et al.
patent: 5652115 (1997-07-01), Marks et al.
patent: 5736146 (1998-04-01), Cohen
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava et al.
patent: 5837251 (1998-11-01), Srivastava
patent: 5846928 (1998-12-01), Kishida
patent: 5869058 (1999-02-01), Cohen
patent: 5891653 (1999-04-01), Attfield
patent: 5910306 (1999-06-01), Alving et al.
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5968526 (1999-10-01), Garman et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava
patent: 6027731 (2000-02-01), Pauza
patent: 6030618 (2000-02-01), Srivastava
patent: 6033561 (2000-03-01), Schoendorfer
patent: 6048530 (2000-04-01), Srivastava
patent: 6136315 (2000-10-01), Srivastava
patent: 6156311 (2000-12-01), Strickland et al.
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava et al.
patent: 6312711 (2001-11-01), Duchateau et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6338945 (2002-01-01), Nicolette
patent: 6403092 (2002-06-01), Pizzo et al.
patent: 6433141 (2002-08-01), Wallen et al.
patent: 6689363 (2004-02-01), Sette et al.
patent: 6709672 (2004-03-01), Henot et al.
patent: 6713608 (2004-03-01), Wallen et al.
patent: 6730302 (2004-05-01), Fujihara et al.
patent: 6797480 (2004-09-01), Srivastava
patent: 6984389 (2006-01-01), Li
patent: 7132109 (2006-11-01), Srivastava
patent: 7179462 (2007-02-01), Srivastava et al.
patent: 7176515 (2007-03-01), Srivastava et al.
patent: 2001/0034042 (2001-10-01), Srivastava
patent: 2002/0001841 (2002-01-01), Kaltoft et al.
patent: 2002/0028207 (2002-03-01), Srivastava
patent: 2002/0037290 (2002-03-01), Armen
patent: 2002/0172682 (2002-11-01), Srivastava
patent: 2002/0192230 (2002-12-01), Srivastava
patent: 2003/0129296 (2003-07-01), Srivastava
patent: 2003/0211971 (2003-11-01), Srivastava
patent: 2004/0022796 (2004-02-01), Srivastava
patent: 2004/0253228 (2004-12-01), Srivastava
patent: 2006/0165710 (2006-07-01), Srivastava
patent: 196 02 985 (1996-01-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/02564 (1990-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/01717 (1992-02-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/14118 (1993-07-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 93/18146 (1993-09-01), None
patent: WO 93/18147 (1993-09-01), None
patent: WO 93/18150 (1993-09-01), None
patent: WO 93/21529 (1993-10-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/04676 (1994-03-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/14471 (1994-07-01), None
patent: WO 94/14976 (1994-07-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/04794 (1997-02-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/06828 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/46739 (1997-07-01), None
patent: WO 98/42752 (1998-10-01), None
patent: WO 98/46743 (1998-10-01), None
patent: WO 99/29834 (1999-06-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/03003 (2000-01-01), None
patent: WO 00/10597 (2000-03-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 00/38760 (2000-07-01), None
patent: WO 00/46246 (2000-08-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 01/91787 (2001-06-01), None
patent: WO 01/92474 (2001-12-01), None
patent: WO 02/07755 (2002-01-01), None
patent: WO 02/11669 (2002-02-01), None
patent: WO 02/15930 (2002-02-01), None
patent: WO 02/30434 (2002-04-01), None
patent: WO 02/32923 (2002-04-01), None
patent: WO 02/34205 (2002-05-01), None
patent: WO 03/015712 (2003-02-01), None
patent: WO 03/090686 (2003-11-01), None
patent: WO 03/092624 (2003-11-01), None
patent: WO 04/035602 (2004-04-01), None
patent: WO 04/74454 (2004-09-01), None
patent: WO 04/075636 (2004-09-01), None
patent: WO 05/120558 (2005-12-01), None
Otto A et al (J. Urol Jan. 1998;159(1):297-303).
Beyrer C (The Hopkins HIV Report Jan. 2003; 15(1):6-7).
Gura (Science, v278, 1997, pp. 1041-1042).
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Bizik et al (Int. J. Cancer 1986; 37:81-88).
Fields et al (J. Virol. Methods 1988; 22:283-294).
U.S. Appl. No. 09/411,075, filed Oct. 4, 1999, P. Srivastava.
Arnold-Schild et al., 1999, “Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells”, J. Immunol. 162: 3757-3760.
Arnold et al., 1995, “Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96”, J Exp Med. Sep. 1;182(3):885-9.
Asea et al., 2000, “HSP70 stimulates cytokine production through a CD14 dependant pathway, demonstrating its dual role as a chaperone and cytokine”, Nature Med. 6: 435-42.
Bardwell et al., 1984, “Major heat shock gene ofDrosophilaand theEscherichia coliheat-inducible dnaK gene are homologous”, Proc Natl Acad Sci U S A. 81(3):848-52.
Bhattacharjee et al., 1999, “Incorporation of non-proteolytic proteins by murine α-2 macroglobulin”, Biochimica et Biophysica Acta 1432:49-56.
Bevan, 1995, “Antigen presentation to cytotoxic T lymphocytes in vivo”, J.Exp. Med. 192: 639-41.
Binder et al., 1998, Cell Stress & Chaperones 3 (Supp. 1): 2.
Blachere et al., 1997, “Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity”, J Exp Med. 186(8):1315-22.
Castellino et al., 2000, “Receptor-mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocmpatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways”, J. Exp. Med. 191: 1957-64.
Chen et al., 1999, “Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System”, J. Immunology 162: 3212-3219.
Chu et al., 1994, “Adjuvant-free in vivo targeting. Antigen delivery by α2-macroglobulin enhances antibody formation”, J. Immun. 152(4):1538-45.
Chu et al., 1994, “Alpha 2-macroglobulin: a sensor for proteolysis”, Ann N Y Acad Sci. 737:291-307.
Chu and Pizzo, 1994, “Alpha 2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation”, Lab Invest. Dec. 1994;71(6):792-812.
Chu and Pizzo, 1993, “Receptor mediated antigen delivery into macrophages. Complexing antigen to α2-macroglobulin enhances presentation into T cells”, J. Immun. 150(1):48-58.
Ciupitu et al., 1998, “Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes”, J Exp Med. 187(5):685-91.
Coutinho et al., 1998, “Alpha-2-macroglobulin r
Binder Robert J.
Srivastava Pramod K.
Jones Day
University of Connecticut Health Center
Yaen Christopher
LandOfFree
Complexes of alpha (2) macroglobulin and antigenic molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complexes of alpha (2) macroglobulin and antigenic molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complexes of alpha (2) macroglobulin and antigenic molecules... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4048113